Better effect of vaccine in MS patients with more B cells


MS patients treated with rituximab have a better effect of covid-19 vaccine if the level of B cells is higher. This is shown by a new study from Uppsala University which is published in the journal JAMA Network Open. In patients with B cells of 40 / µL (microliters) or more, 9 out of 10 patients developed a protective level of antibodies, while there were significantly fewer among those with lower levels.

Read the press release on Mynewsdesk (in Swedish).
Read more about the study (in Swedish).